Eli Lilly and Company vs AbbVie Inc. — Stock Comparison
Q·Score Breakdown
8.2
Buy
Overall
6.1
Hold
Quality
Health
Growth
Valuation
Sentiment
LLY
Earnings growing 51% year-over-year on 43% revenue growth.
ABBV
72% of 32 covering analysts rate it Buy or Strong Buy.
⚠ earnings contracting 46% year-over-year.
Analyst Consensus
BUY
Target $1202.34 (+30.5%)
29 analysts
BUY
Target $249.27 (+16.6%)
30 analysts
Fundamentals
LLY
ABBV
40.1×
Trailing P/E
104.8×
21.9×
Forward P/E
13.2×
31.7%
Profit Margin
5.8%
83.0%
Gross Margin
72.0%
101.2%
ROE
—
42.6%
Revenue Growth
12.4%
51.4%
Earnings Growth
-45.8%
0.50
Beta
—
—
Price / Book
—
$823.3B
Market Cap
$378.2B
$624 – $1,134
52-Week Range
$177 – $245
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.